Regeneron Pharmaceuticals, Inc.
HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4

Abstract:

The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the K.sub.D of 500 pM or less, as measured by surface plasmon resonance.